Amal Therapeutics develops and commercializes peptide-based therapeutic vaccines for the treatment of cancer.
Business Model:
Revenue: $150M
Employees: 51-200
Amal Therapeutics was acquired by
Boehringer Ingelheim.
The acquisition happend on 2019-07-15.
Details of the transaction were not public
Address: 64 av. of the Roseraie
City: Geneva
State: geneva
Zip: 1205
Country: CH
Amal Therapeutics develops and commercializes peptide-based therapeutic vaccines for the treatment of cancer.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|